NUVL – nuvalent, inc. - class a (US:NASDAQ)

News

Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference
Nuvalent, Inc. (NASDAQ: NUVL) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $99.00 price target on the stock.
FDA grants breakthrough therapy status for Nuvalent's NVL-655 [Yahoo! Finance]
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655 [Yahoo! Finance]
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com